乳腺癌与2型糖尿病关系研究进展

李 娜1, 王淼 舟*2
1、青海大学
2、青海大学附属医院

摘要


随着对乳腺癌与2型糖尿病之间关联的研究日益增多，揭示了二者可能共享的病理生理机制。这篇综述深入研究了其生物学机制，强调了胰岛素抵抗和炎症途径是癌症发病机制的关键贡献者。来自队列研究和荟萃分析的证据表明，两者之间存在显著的相关性。然而，通晓二者之间的因果关系仍然是一个挑战，这给临床综合治疗及疾病的综合管理也带来了巨大困难。这篇文章强调了先进的生物标志物识别和跨学科的研究方法在探究疾病潜在联系并制定综合的治疗、干预措施的关键作用。该综述认为，了解2型糖尿病和乳腺癌之间的复杂关系可能为改善疾病预后、革新治疗干预打开大门。

关键词


乳腺癌；2型糖尿病；胰岛素抵抗；流行病学研究；治疗策略

全文:

PDF


参考


[1]G. Shlomai, B. Neel, D. LeRoith, and E. J. Gallagher, “Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy,” J Clin Oncol, vol. 34, no. 35, pp. 4261-4269, Dec. 2016, doi: 10.1200/JCO.2016.67.4044.

[2]S. T, E. A, L. D, and G. Ej, “Obesity, Type 2 Diabetes, and Cancer Risk,” Frontiers in oncology, vol. 10, Feb. 2021, doi: 10.3389/fonc.2020.615375.

[3]P. P et al., “An Overview of Recent Findings that Shed Light on the Connection between Fat and Cancer,” Endocrine, metabolic & immune disorders drug targets, vol. 24, no. 2, 2024, doi: 10.2174/1871530323666230724141942.

[4]W. X and D. S, “The biological and pharmacological connections between diabetes and various types of cancer,” Pathology, research and practice, vol. 227, Nov. 2021, doi: 10.1016/j.prp.2021.153641.

[5]W. Y, L. X, L. Q, C. C, and Z. L, “Adipose tissue-to-breast cancer crosstalk: Comprehensive insights,” Biochimica et biophysica acta. Reviews on cancer, vol. 1877, no. 5, Sep. 2022, doi: 10.1016/j.bbcan.2022.188800.

[6]P. A, G. M, P. Sg, N. Ae, and G. Ef, “New insights in the molecular pathways linking obesity, type 2 diabetes and cancer,” Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, vol. 60, no. 4, 2019, Accessed: Jul. 26, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32239086/

[7]S. Ms, M. Mm, A. Ma, H. Ms, and I. Mz, “Bioinformatics and network biology approach to identifying type 2 diabetes genes and pathways that influence the progression of breast cancer,” Heliyon, vol. 9, no. 5, Dec. 2023, doi: 10.1016/j.heliyon.2023.e16151.

[8]W. M, Y. Y, and L. Z, “Diabetes and cancer: Epidemiological and biological links,” World journal of diabetes, vol. 11, no. 6, Jun. 2020, doi: 10.4239/wjd.v11.i6.227.

[9]J. W. Kim, J. H. Kim, and Y. J. Lee, “The Role of Adipokines in Tumor Progression and Its Association with Obesity,” Biomedicines, vol. 12, no. 1, p. 97, Jan. 2024, doi: 10.3390/biomedicines12010097.

[10]H. N et al., “Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry,” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol. 21, no. 3, Mar. 2012, doi: 10.1158/1055-9965.EPI-11-0979.

[11]B. X et al., “Bioinformatics Combined With Biological Experiments to Identify the Pathogenetic Link of Type 2 Diabetes for Breast Cancer,” Cancer medicine, vol. 14, no. 7, Apr. 2025, doi: 10.1002/cam4.70759.

[12]X. F et al., “Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study,” British journal of cancer, vol. 129, no. 4, Sep. 2023, doi: 10.1038/s41416-023-02345-4.

[13]J. N, K. Ka, T. Rw, B. S, and C.-F. D, “Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis,” Breast cancer research and treatment, vol. 202, no. 1, Nov. 2023, doi: 10.1007/s10549-023-07043-6.

[14]S. P, A. I, K. Ma, and M.-K. N, “The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances,” Cancer management and research, vol. 11, Apr. 2019, doi: 10.2147/CMAR.S200059.

[15]徐钰，徐婷 and XU Yu X. T.，“二甲双胍可能通过Hippo-YAP通路抑制HER-2阳性乳腺癌细胞的增殖和促进凋亡，”南方医科大学学报，vol. 42, no. 5, p. 740, May 2022, doi: 10.12122/j.issn.1673-4254.2022.05.16.

[16]W. B et al., “The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer,” ESMO open, vol. 7, no. 6, Dec. 2022, doi: 10.1016/j.esmoop.2022.100648.

[17]“(PDF) The anti-proliferative role of metformin in non-diabetic female patients with breast cancer: systematic review and meta-analysis of randomized control trials.” Accessed: Jul. 31, 2025. [Online]. Available: https://www.researchgate.net/publication/351847859_The_anti-proliferative_role_of_metformin_in_non-diabetic_female_patients_with_breast_cancer_systematic_review_and_meta-analysis_of_randomized_control_trials

[18]C. A. Liu, C. Tjoa, F. G. Torizal, I. Huang, and A. Kurniawan, “P87-1 The role of lifestyle interventions in preventing breast cancer recurrence: a systematic review,” Annals of Oncology, vol. 35, p. S1391, Oct. 2024, doi: 10.1016/j.annonc.2024.07.464.

[19]S. E, H. C, K. C, V. B, and D. Dm, “Lifestyle Interventions for Four Conditions: Type 2 Diabetes, Metabolic Syndrome, Breast Cancer, and Prostate Cancer [Internet],” PubMed. Accessed: Jul. 26, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/25473696/

[20]A. M, K. E, O. I, M. B. B, D. D, and A. Z, “The Effect of Exercise on Life Quality and Depression Levels of Breast Cancer Patients,” Asian Pacific journal of cancer prevention : APJCP, vol. 22, no. 3, Jan. 2021, doi: 10.31557/APJCP.2021.22.3.725.

[21]陈佩贤 and 叶国麟，“乳腺癌患者生存质量研究现状，”中国普外基础与临床杂志，2021, Vol. 28, Pages 1510-1515. Accessed: Jul. 26, 2025. [Online]. Available: https://www.gensurg.cn/article/10.7507/1007-9424.202106032

[22]B. Mj, R.-S. Jl, and Q.-F. M, “Mitochondrial Inhibition: a Treatment Strategy in Cancer?,” Current oncology reports, vol. 23, no. 4, Mar. 2021, doi: 10.1007/s11912-021-01033-x.

[23]R. I, A. Mt, and I. M, “Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways,” Frontiers in oncology, vol. 10, Jan. 2021, doi: 10.3389/fonc.2020.600824.

[24]S. W and S. M, “Variable Drug-Target Exposure, Tumor Signatures, and Combinatorial Targeted Treatment: Approaches of Personalized Medicine in Breast Cancer,” Journal of personalized medicine, vol. 12, no. 6, Jan. 2022, doi: 10.3390/jpm12060917.

[25]P. Lc et al., “Diabetes and cancer co-management: patient-reported challenges, needs, and priorities,” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol. 31, no. 2, Feb. 2023, doi: 10.1007/s00520-023-07604-x.

[26]D. M et al., “Patterns of chronic disease management and health outcomes in a population-based cohort of Black women with breast cancer,” Cancer causes & control : CCC, vol. 32, no. 2, Feb. 2021, doi: 10.1007/s10552-020-01370-5.

[27]N. H, “Dawn of a new era of diabeto-oncology,” Journal of diabetes investigation, vol. 11, no. 4, Jul. 2020, doi: 10.1111/jdi.13204.

[28]A. Kt, L. L, M. E, S. M, and G. M, “Exploring the association between diabetes and breast cancer morbidity: considerations for quality care improvements among Latinas,” International journal for quality in health care : journal of the International Society for Quality in Health Care, vol. 32, no. 2, Apr. 2020, doi: 10.1093/intqhc/mzz130.

[29]L. D et al., “Clinical significance of lipid pathway-targeted therapy in breast cancer,” Frontiers in pharmacology, vol. 15, Jun. 2025, doi: 10.3389/fphar.2024.1514811.


Refbacks

  • 当前没有refback。